Clinical trialNCT00003283CompletedPhase 2Interventional

Octreotide With or Without Prednisone in Treating Patients With Metastatic or Recurrent Thymoma

SponsorEastern Cooperative Oncology GroupEnrollment38Thymoma and Thymic Carcinoma

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to compare the effectiveness of octreotide alone or with prednisone in treating patients with metastatic or recurrent thymoma.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

David S. Ettinger, MD
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Study Chair
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

25 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

South Africa

Pretoria Academic Hospitals
Pretoria, South Africa

United States

Veterans Affairs Medical Center - Palo Alto
Palo Alto, California, United States
Stanford University Medical Center
Stanford, California, United States
Ccop - Colorado Cancer Research Program, Inc.
Denver, Colorado, United States
Sylvester Cancer Center, University of Miami
Miami, Florida, United States
Emory University Hospital - Atlanta
Atlanta, Georgia, United States
Veterans Affairs Medical Center - Atlanta (decatur)
Decatur, Georgia, United States
Robert H. Lurie Comprehensive Cancer Center, Northwestern University
Chicago, Illinois, United States
Veterans Affairs Medical Center - Lakeside Chicago
Chicago, Illinois, United States
Ccop - Carle Cancer Center
Urbana, Illinois, United States
Veterans Affairs Medical Center - Indianapolis (roudebush)
Indianapolis, Indiana, United States
Ccop - Cedar Rapids Oncology Project
Cedar Rapids, Iowa, United States
Johns Hopkins Oncology Center
Baltimore, Maryland, United States
New England Medical Center Hospital
Boston, Massachusetts, United States
Ccop - Kalamazoo
Kalamazoo, Michigan, United States
Ccop - Metro-Minnesota
Saint Louis Park, Minnesota, United States
Veterans Affairs Medical Center - Albany
Albany, New York, United States
University of Rochester Cancer Center
Rochester, New York, United States
Albert Einstein Comprehensive Cancer Center
The Bronx, New York, United States
Ireland Cancer Center
Cleveland, Ohio, United States
Ccop - Geisinger Clinic and Medical Center
Danville, Pennsylvania, United States
Fox Chase Cancer Center
Philadelphia, Pennsylvania, United States
Hahnemann University Hospital
Philadelphia, Pennsylvania, United States
Vanderbilt-Ingram Cancer Center
Nashville, Tennessee, United States
Veterans Affairs Medical Center - Nashville
Nashville, Tennessee, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Octreotide →Prednisone →

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 13 Oct 1998
Primary completion: 30 Sept 2003
Completion: —
Last update posted: 15 Jun 2023
Registered enrollment: 38
Registry id: NCT00003283

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.